RJA
EDIT icon

Raymond James & Associates’s Editas Medicine EDIT Stock Holding History

Raymond James & Associates’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.91M Buy
561,371
+34,556
+7% +$150K ﹤0.01% 2251
2024
Q2 		$2.46M Buy
526,815
+174,993
+50% +$987K ﹤0.01% 2036
2024
Q1 		$2.61M Buy
351,822
+92,763
+36% +$771K ﹤0.01% 1998
2023
Q4 		$2.62M Sell
259,059
-15,244
-6% -$134K ﹤0.01% 1936
2023
Q3 		$2.14M Buy
274,303
+14,994
+6% +$129K ﹤0.01% 1979
2023
Q2 		$2.13M Buy
259,309
+154,566
+148% +$1.35M ﹤0.01% 2017
2023
Q1 		$759K Buy
104,743
+7,516
+8% +$66.8K ﹤0.01% 2639
2022
Q4 		$862K Buy
97,227
+11,319
+13% +$124K ﹤0.01% 2521
2022
Q3 		$1.05M Sell
85,908
-52,571
-38% -$819K ﹤0.01% 2360
2022
Q2 		$1.64M Sell
138,479
-21,642
-14% -$290K ﹤0.01% 2116
2022
Q1 		$3.05M Buy
160,121
+100,971
+171% +$1.88M ﹤0.01% 1845
2021
Q4 		$1.57M Sell
59,150
-4,711
-7% -$162K ﹤0.01% 2332
2021
Q3 		$2.62M Buy
63,861
+498
+0.8% +$27.3K ﹤0.01% 1907
2021
Q2 		$3.59M Sell
63,363
-18,464
-23% -$682K ﹤0.01% 1722
2021
Q1 		$3.44M Buy
81,827
+20,485
+33% +$1.17M ﹤0.01% 1674
2020
Q4 		$4.3M Sell
61,342
-20,192
-25% -$829K ﹤0.01% 1422
2020
Q3 		$2.29M Sell
81,534
-18,502
-18% -$603K ﹤0.01% 1667
2020
Q2 		$2.96M Buy
100,036
+5,380
+6% +$141K ﹤0.01% 1490
2020
Q1 		$1.88M Buy
94,656
+42,318
+81% +$1.07M ﹤0.01% 1609
2019
Q4 		$1.55M Sell
52,338
-7,806
-13% -$195K ﹤0.01% 1992
2019
Q3 		$1.37M Buy
60,144
+1,296
+2% +$32.1K ﹤0.01% 1995
2019
Q2 		$1.46M Buy
58,848
+42,050
+250% +$1M ﹤0.01% 1986
2019
Q1 		$411K Sell
16,798
-11,548
-41% -$261K ﹤0.01% 2794
2018
Q4 		$645K Sell
28,346
-5,432
-16% -$148K ﹤0.01% 2372
2018
Q3 		$1.07M Buy
33,778
+1,505
+5% +$48.6K ﹤0.01% 2212
2018
Q2 		$1.16M Buy
32,273
+172
+0.5% +$6.09K ﹤0.01% 2095
2018
Q1 		$1.06M Buy
+32,101
New +$1.14M ﹤0.01% 2091

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James & Associates's EDIT Position: Q3 2024 in Review

Raymond James & Associates increased its Editas Medicine (EDIT) stake by 6.6% in Q3 2024, buying an estimated $150K and bringing the position to 561,371 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #2251.

Raymond James & Associates first reported a position in EDIT in Q1 2018 and has held it in 27 quarters since. The position peaked at $4.3M in Q4 2020. 229 funds tracked by Wall St. Rank hold EDIT as of Q3 2024.

  • Raymond James & Associates held 561,371 shares of Editas Medicine worth $1.91M as of Q3 2024.
  • Raymond James & Associates bought 34,556 Editas Medicine shares in Q3 2024, an estimated $150K.
  • Editas Medicine made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2251 holding.
  • Raymond James & Associates first reported a position in Editas Medicine in Q1 2018 and has held it in 27 quarters since.
  • Raymond James & Associates's Editas Medicine position peaked at $4.3M in Q4 2020.
  • 229 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.